Japan Price-Setting Decision Frees Drug Makers To Release Generics
This article was originally published in PharmAsia News
Executive Summary
Armed with government-set prices, several makers of generic drugs in Japan plan to launch anti-cancer drugs through the rest of the year. Sawai Pharmaceutical released 34 as soon as the Health Ministry announced official prices, and Towa Pharmaceutical plans to introduce 14 over the next few weeks. Nichi-Iko Pharmaceutical says it plans to release 26 generics over the course of the year and Taiyo Pharmaceutical Industry plans 17. (Click here for more - a subscription may be required
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.